Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00279955 · ClinicalTrials.gov registry record
PARTNERS HF: Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure
A clinical trial, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Completed
- Registry status
- 1,024
- Enrollment target
NCT00279955: Completed study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
NCT00279955 is a clinical trial that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 1,024 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00279955 has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- COMPLETED
- Registry status
- 1,024 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the value of diagnostic data obtained from Medtronic implantable cardioverter defibrillators (ICDs) with cardiac resynchronization therapy (CRT) to evaluate cardiovascular and heart failure related adverse events and health care utilization.
Primary Outcome
Number of participates with HF realted adverse event will be reported. Time to the first HF related Adverse event in the "Follow-up Period" from the 6-month visit to the 12-month visit is compared between two risk groups. The goal was to test if there is a significant difference in time to first HF-related adverse event between two groups. A heart failure related (HF-related) adverse event is defined as an adverse event that results in a subject's worsening HF or related to the heart's inability
Interventions
- DEVICE Cardiac Resynchronization Therapy Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,024 participants |
| Start Date | 2004-06 |
| Est. Completion | 2008-06 |
What the finished NCT00279955 record still lists
NCT00279955 is an observational study that tracks outcomes without assigning an intervention. Its 1,024 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Cardiac Resynchronization Therapy Device is the first listed.
NCT00279955 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00279955 about?
NCT00279955 is a clinical study titled "PARTNERS HF: Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure". The purpose of this study is to determine the value of diagnostic data obtained from Medtronic implantable cardioverter defibrillators (ICDs) with cardiac resynchronization therapy (CRT) to evaluate cardiovascular and heart failure related adverse events and health care utilization.
What is the current status of trial NCT00279955?
This trial is currently completed. The enrollment target is 1,024 participants. The study started on 2004-06. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00279955?
The interventions under investigation include: Cardiac Resynchronization Therapy Device (DEVICE).
Who is sponsoring clinical trial NCT00279955?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06888011 · 1,024 participants · NA
iAmHealthy Clinical Practice Guideline (CPG)
- NCT02200276 · 1,025 participants · NA
Influenza Immunization in Adults Over Age 75
- NCT02296450 · 1,025 participants
Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments
- NCT07216703 · 1,023 participants · Phase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia